The US Pharma Market: Landscape, Key Players, and Terminology. FDA, pipeline, branded drug, generic drug, blockbuster, payer, formulary, orphan drug, market exclusivity, big pharma, bring a drug to market, go off patent/go generic, patent cliff, out-of-pocket costs, gain formulary access. This is for korean bio professionals who are at a B1-B2 level and are elevating their english skills through natural conversation on these topics.

Big Pharma

Refers to large pharmaceutical companies that have the financial and temporal resources required to bring a drug to market.

FDA

The Food and Drug Administration, which serves as the regulatory gatekeeper for drugs in the United States.

Pipeline

A measure of a pharmaceutical company's future value based on the drugs under development.

Blockbuster drug

A drug that generates over a billion dollars in sales, often crucial for a company's revenue.

Branded drugs

Medications sold under a proprietary, trademarked name.

Generic drugs

Medications that are equivalent to branded drugs but sold under their chemical name without trademark.

Patent cliff

The point when a drug's patent expires, allowing generic versions to enter the market.

Market exclusivity

A period during which a drug's manufacturer has sole rights to sell the drug, often following patent expiration.

Orphan drugs

Medications developed specifically to treat rare diseases, often incentivized by the government.

Payer

Insurance companies that influence drug coverage and reimbursement in the U.S. healthcare system.

Formulary access

The process through which a drug is included in an insurance formulary, determining coverage.

Out-of-pocket costs

Expenses that patients must pay for medical services or medications that are not covered by insurance.